Collectively, our findings demonstrate that adding GLP-1RA to SGLT2i therapy is a promising therapeutic strategy for patients with MASLD and T2D, offering significant improvements in mortality, liver outcomes, and kidney protection
An open-label trial of riluzole in patients with treatment-resistant major depression
PMID: 35450390 Article Published Date : Mar 31, 2022 Study Type : Animal Study [+] Paeoniflorin attenuates depressive behaviors in systemic lupus erythematosus.Jun 30, 2018 Click here to read the entire abstract Pubmed Data : Biomed Pharmacother
The most significant changed plasma metabolites in MS-affected Chinese patients were amino acid, lipid and their derivatives, of which representative differentially abundant metabolites such as L-glutamic acid, L-leucine and L-isoleucine, as well as sphingosine 1-phosphate and sphinganine 1-phosphate, were also identified in Caucasian populations with MS ( bona fide universal biomarkers for MS
These injections often lead to temporary weight loss, with many individuals regaining weight once the treatment is discontinued